What are the recent financial highlights of MANGALAM DRUG & CHEM LTD?

MANGALAM DRUG & CHEM LTD recently reported a total revenue of ₹346.74 Cr and a net profit margin of 2.94%. These metrics reflect the company’s consistent financial performance.

What are the key financial metrics of MANGALAM DRUG & CHEM LTD?

Key financial metrics include a trailing P/E ratio of 11.52795, forward P/E of , book value of ₹93.515, price-to-book ratio of 0.7938833, and a market capitalization of ₹1.18 billion.

What does MANGALAM DRUG & CHEM LTD do?

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers API products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; and ortho phenoxy methane sulfonanilide, tenofovir alafenamide base, and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol; bictegravir Na, aripiprazole, risperidone, olanzapine, and etodolac; and develops tafenoquine succinate and pretomanid. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. The company was incorporated in 1972 and is based in Mumbai, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Mangalam

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Mangalam

Latest updates related to Mangalam

Sr No.	Title	Sentiment
1	'I had let the school down': Kumar Mangalam Birla shares childhood lesson in humility that shaped him as a human’ Fortune India	🔄
2	Mangalam Cement Faces Financial Challenges Amid Reassessment of Market Position and Performance MarketsMojo	🔄
3	Stock split 2025: Mangalam Global, Coastal Corporation to trade ex-split today Mint	🔄
4	‘I choked up’: Kumar Mangalam Birla, Peyush Bansal, and more get surprise tributes at ET Awards Economic Times	🔄
5	‘We will be embracing a U3 world’: Kumar Mangalam Birla shares his vision for 2025 Business Today	🔄
6	Mahesh Navathar appointed as Additional Executive Director of Mangalam Organics Indian Chemical News	🔄
7	Mangalam Drugs Consolidated December 2024 Net Sales at Rs 88.71 crore, down 8.86% Y-o-Y Moneycontrol	🔄
8	Kumar Mangalam Gets Ready to Fight for Birla’s Future Outlook Business	🔄
9	Aditya Birla Group chairman Kumar Mangalam Birla shares his vision for 2025 Hindustan Times	🔄
10	Mangalam Seeds Faces Revenue Decline Amid Rising Financial Obligations and Market Underperformance MarketsMojo	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

Explore More Stocks

PRITIKA GOLDSTAR SPAL MOTHERSON BHARATWIRE TCS ACCENTMIC ZENITHDRUG MODISONLTD ROCKINGDCE